Avapritinib is Used for treating advanced systemic mastocytosis, including aggressive types, and unresectable or metastatic gastrointestinal stromal tumors with a specific mutation. It was first introduced by Blueprint Medicines Corp in its drug Ayvakit on Jan 9, 2020.

Avapritinib Patents

Given below is the list of patents protecting Avapritinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Ayvakit	US11827642	Compositions useful for treating disorders related to KIT	Oct 15, 2034	Blueprint Medicines
Ayvakit	US11964980	Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making	Apr 10, 2040	Blueprint Medicines
Ayvakit	US11999744	Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making	Apr 10, 2040	Blueprint Medicines
Ayvakit	US9200002	Compositions useful for treating disorders related to KIT	Oct 15, 2034	Blueprint Medicines
Ayvakit	US9944651	Compositions useful for treating disorders related to kit	Oct 15, 2034	Blueprint Medicines
Ayvakit	US9994575	Compositions useful for treating disorders related to kit	Oct 15, 2034	Blueprint Medicines

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳